RecruitingPhase 1NCT06894745

PET [89Zr]DFO-starPEG in Solid Tumors

Positron Emission Tomography (PET) Imaging of the Enhanced Permeability and Retention (EPR) Effect With [89Zr]DFO-starPEG in Patients With Solid Tumors

Sponsor

Robert Flavell, MD, PhD

Enrollment

13 participants

Start Date

Jun 2, 2025

Study Type

INTERVENTIONAL

Conditions

Solid Tumor Solid Carcinoma Soft Tissue Lesion

Summary

This is a first-in-human, pilot study of the novel PET-imaging radiotracer \[89Zr\]DFO-starPEG. The study is designed to obtain preliminary data to support future development of this agent as an imaging surrogate to visualize enhanced permeability and retention (EPR)-mediated tracer uptake before administration of EPR-based nanomedicines.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called 89-zr-dfo-star polyethylene glycol (StarPEG), a procedure called Specimen Collection, and others for people with soft tissue lesion, solid carcinoma, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.